VANCOUVER, British Columbia--(BUSINESS WIRE)--Jan. 27, 2004--BioPartnering North America:
WHAT: Second Annual BioPartnering North America (BPN) Conference
BNP is a partnership between BC Biotech, BioAlberta, BIOTECanada, Technology Vision Group LLC, and industry leaders. It is the North American version of the distinguished BioPartnering Europe conference held in London each October.
WHEN: February 8-10, 2004
WHERE: Westin Bayshore Resort & Marina, Vancouver, Canada
WHY: Partnering is a critical component to the success of biotechnology companies, providing companies at all levels with an opportunity to collaborate with complementary organizations. BPN is a venue in which companies at various stages of development can foster relationships to progress their drug candidates and gain exposure to information on financing, marketing strategy and support, emerging technologies, and dealing with regulators such as the U.S. FDA.
WHO: - More than 600 delegates representing over 300 companies from 25 countries
- Fifty-six biopharmaceutical and diagnostics companies will make Open House Presentations and 16 young companies from around the world will make 15-minute podium presentations
- Mr. James Watson, Director, Strategic Partnering Services, Burrill & Company, a life sciences merchant bank
- Natalie Dakers, chair, BC Biotech
- Paul Stinson, executive director, BC Biotech
- Myka Osinchuk, executive director, BioAlberta
- Janet Lambert, president, BIOTECanada
- Tracy Lefteroff, Global Managing Partner, Life Sciences Industry, PricewaterhouseCoopers
- Dr. Bill Hunter, president & CEO Angiotech Pharmaceuticals
Second Annual BioPartnering North America Conference; Westin Bayshore Resort & Marina, Vancouver, Canada
February 8-10, 2004
BioPartnering North American (BPN) is a partnership between BC Biotech, BioAlberta, BIOTECanada, Technology Vision Group LLC, and leading pharmaceutical, biotechnology, financial, and service companies from around the world. Held in Vancouver, B.C., it is the North American version of the distinguished BioPartnering Europe conference held in London.
Partnering is a critical component to the success of biotechnology companies, providing companies at all levels with an opportunity to collaborate with complementary organizations to progress their drug candidates. BPN is a venue in which companies at various stages of development can foster relationships and gain exposure to information on financing, emerging technologies, marketing strategy and support, and dealing with regulators such as the U.S. FDA. Smaller companies gain from the experience larger companies have to offer, and larger, more mature partner companies have the opportunity to enhance their product pipelines, benefiting from the R&D capabilities of smaller companies.
With over 65 per cent of North American biotech companies located west of the Rockies, Vancouver, BC, is a perfect place to hold BPN, providing easy access to a beautiful location where more than 600 delegates representing over 300 companies from 25 countries can come together to discuss the evolution of the industry.
A key feature of BPN is the Open House Presentations. This year 56 biopharmaceutical and diagnostics companies will showcase various aspects of their businesses including science and technology, partnering strategies, developmental programs, commercialization plans, product opportunities and manufacturing capabilities. Each company will offer interactive presentations in specially constructed booths designed to house small group meetings and support the two-hour period of informal discussions made available to business development executives.
BPN also showcases a number of young companies from around the world. Sixteen companies will offer 15-minute podium presentations in the main plenary hall and will be available for private discussions after each session.
There are several new features at this year’s conference including workshops on cross-border financing, patent law, and the investment outlook for 2004. One plenary session on Monday, February 9th, is devoted to building a sustainable biotech cluster in BC, while the final plenary session on Tuesday, February 10th, will deal with the importance of Pharmacogenomics - A New Paradigm for Drug Development.
Canadian Biotech Facts - 2003:
Canada’s biotech sector includes more than 400 companies, ranking second in the world after the US in terms of number of firms Canadian biotechnology companies raised over $1.9 billion in 2003 and total financing was almost double of that raised in 2002 Vancouver-based NeuroMed Technologies closed the largest private financing deal of the year - a Series C financing of US$32 million Vancouver-based Angiotech Pharmaceuticals raised the largest public financing deal of the year at $339 million For full conference information, please visit http://www.techvision.com/bpn.
-------------------------------------------------------------------------------- Contact:
BioPartnering North America
James Hoggan & Associates
Miriam Zitner, 604-742-4257
Email: mzitner@hoggan.com
or
John Kageorge, 604-742-4265
Email: jkageorge@hoggan.com
-------------------------------------------------------------------------------- Source: BioPartnering North America
